GL1X · GenesisL1 explorer

Research workbench

Viability of a drug-resistant HIV-1 protease mutant: structural insights for better antiviral therapy

Analyse Viability of a drug-resistant HIV-1 protease mutant: structural insights for… in the GL1X research workbench: secondary structure, accessibility, pockets, interfaces, conservation, variants, modifications, peptides, crosslinks and neighbours on the 3D structure.

PDB
1MTB
Type
protein
Length
200 residues
Chains
2
Method
x-ray diffraction
Collection
MolNFT v1 / PDB
Contract
0xDE3723766Bc32dcACD03C17BaA400A7B36837Eba
Owner
0x3396CDB397284571d12822B4ae1189a8E22AAAAA
Molecule
Protease retropepsin
EC
3.4.23.16
UniProt
P03369
Ligands
QNC, DIQ, NTB
Pockets
1 · best druggability 0.64

Structure

x-ray diffraction · 2 distinct chains · 7% helix, 55% strand (DSSP).

ChainMoleculeTypeResiduesSecondary structureUniProt
AProtease retropepsin (EC 3.4.23.16)protein1017% helix, 55% strandP03369
BProtease retropepsin (EC 3.4.23.16)protein997% helix, 55% strandP03369

Ligands and binding sites

  • QNC · quinoline-2-carboxylic acid · ligand · chains A, B
  • DIQ · 2-methyl-decahydro-isoquinoline-3-carboxylic acid · ligand · chains A, B
  • NTB · Tertiary-butylamine · ligand · chains A, B

Binding sites are the residues within 4.5 Å of a ligand's heavy atoms.

Pockets

1 pocket found on a 1 Å grid, 1 with a druggability of 0.5 or more.

PocketVolume (ų)DruggabilityBuriednessLining residuesInside
12210.640.8227DIQ, NTB

Interfaces

1 interface between chains.

  • A–B · 1934 Ų buried · 39 hydrogen bonds · protein-protein

Modifications

Observed in the structure: 2 covalent, 1 modified (covalent ligand, nonstandard).

Compared structures

  • 1MTB · Viability of a drug-resistant HIV-1 protease mutant: structural insights for better… · the same entry in another collection · chain B against B, TM-score 1.00

Analyse

GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.